@prefix this: <http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA> .
@prefix sub: <http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix nkg: <https://w3id.org/um/neurodkg/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:association rdf:object <https://identifiers.org/MONDO:0001945>;
    rdf:predicate bl:treats;
    rdf:subject <https://identifiers.org/CHEBI:3182>;
    a rdf:Statement;
    rdfs:label "Bromocriptine mesylate tablets are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing \"end of dose failure\" on levodopa therapy.";
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    bl:provided_by "NeuroDKG";
    bl:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93a0696b-b261-4262-9e06-f3180b419f8f>;
    bl:relation nkg:SymptomaticReliefIndication .
  
  <https://identifiers.org/CHEBI:3182> bl:category bl:Drug .
  
  <https://identifiers.org/MONDO:0001945> bl:category bl:Disease .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "ZHyrCk2z7qXvlzKEAzZQfFVAnc2w0z+nW4bse6zUIMp2SCax3AqnRRlqQAiORr37W9rnr7DwxLMi3HdsOIbMa9rtLKEFBUBQYiwXmG70Yy80Yp5o/9oJG1YUSL7QfmuLA5OWq3UOgreM1u11v6GYXMi6oEy5HV1cadB6O59EgC0=";
    npx:hasSignatureTarget this: .
  
  this: dct:created "2021-03-28T20:10:59.894+02:00"^^xsd:dateTime;
    dct:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RA59AEpaWRaR9sjdA0-n4zaQWdiZ6--iGafMrjrDAOheI> .
}